Three major consumer staples and pharmaceutical companies raised their dividends in July 2026, offering income investors fresh confirmation that established blue-chip names continue to prioritize shareholder returns even as Treasury yields hover near 4.6 percent. J.M. Smucker Co. lifted its quarterly payout to $1.12 per share, PepsiCo declared a $1.48 quarterly dividend representing a 4 percent increase, and AbbVie raised its quarterly distribution to $1.73 on the strength of a twelve-year streak of annual increases.
J.M. Smucker raises quarterly dividend to $1.12
The J.M. Smucker Co. board approved an increase in the quarterly dividend from $1.10 to $1.12 per share. The modest two-cent lift reflects the company’s disciplined approach to capital allocation and its confidence in the underlying cash flows from its portfolio of packaged food brands. Smucker owns iconic names including Folgers, Jif, and Milk-Bone, which generate recurring revenue streams that support steady payout growth.
At the new rate, Smucker shares offer an annualized dividend of $4.48 per share. The increase marks another year of uninterrupted distribution growth for a company that has prioritized returning cash to shareholders across multiple economic cycles. For income investors focused on consumer staples, the reliability of Smucker’s brands provides a defensive anchor during periods of market volatility.
Smucker has historically maintained a payout ratio in the conservative range for the packaged food sector. This discipline allows the company to reinvest in brand marketing and product innovation while still returning meaningful capital to shareholders. The July 2026 increase suggests management views current earnings power as sustainable and does not anticipate near-term pressure that would threaten the dividend trajectory.
PepsiCo declares $1.48 quarterly with 4 percent boost
PepsiCo announced a quarterly dividend of $1.48 per share, representing a 4 percent increase over the prior rate. The beverage and snack giant has now raised its dividend for more than fifty consecutive years, placing it among the most reliable dividend growth stocks in the S&P 500. PepsiCo’s diversified revenue base spans carbonated drinks, non-carbonated beverages, and the Frito-Lay snack division.
The $1.48 quarterly rate translates to $5.92 annually. PepsiCo’s yield sits comfortably above the S&P 500 average and competes favorably with the 10-year Treasury yield near 4.6 percent. For investors who value both current income and growth potential, PepsiCo offers a middle ground between low-yield tech names and high-yield but slower-growing utilities.
Analysts at multiple firms have cited PepsiCo’s pricing power and global distribution network as structural advantages that support continued dividend growth. The company has demonstrated an ability to pass through input cost inflation while maintaining volume, a dynamic that protects margins and cash flows. The 4 percent increase in July 2026 is consistent with PepsiCo’s historical mid-single-digit annual dividend growth rate.
AbbVie lifts payout to $1.73 on 12-year streak
AbbVie raised its quarterly dividend to $1.73 per share, up from $1.64 in 2025, marking the twelfth consecutive year of annual dividend increases since spinning off from Abbott Laboratories. The pharmaceutical company generates substantial cash flows from its immunology and oncology portfolios, with Humira still contributing meaningfully to revenue despite biosimilar competition.
The new rate produces an annualized dividend of $6.92 per share. AbbVie’s yield has historically ranked among the higher payouts in the large-cap pharmaceutical sector, attracting income investors who also want exposure to drug development upside. The company’s pipeline includes newer immunology drugs Skyrizi and Rinvoq, which are expected to offset Humira revenue declines over the next several years.
Management has signaled a commitment to returning at least half of free cash flow to shareholders through dividends and buybacks. The July 2026 increase reinforces that commitment and suggests confidence in the transition from Humira dependence to a more diversified revenue base. For investors with multi-year time horizons, AbbVie’s combination of current yield and pipeline optionality remains attractive.
Dividend comparison table
| Company | Ticker | New Quarterly | Annualized | Increase |
|---|---|---|---|---|
| J.M. Smucker | SJM | $1.12 | $4.48 | 1.8% |
| PepsiCo | PEP | $1.48 | $5.92 | 4.0% |
| AbbVie | ABBV | $1.73 | $6.92 | 5.5% |
How these yields compare to Treasuries
The 10-year Treasury yield traded near 4.55 to 4.6 percent in mid-July 2026, creating a competitive backdrop for dividend stocks. At current prices, PepsiCo’s forward yield sits slightly above the 10-year Treasury rate, while Smucker and AbbVie offer yields that are competitive or higher depending on the share price at purchase. The key distinction is that Treasury yields are fixed while dividend stocks offer growth potential that can outpace inflation over time.
A retiree allocating $100,000 to a basket of these three stocks would generate approximately $4,800 to $5,600 in annual dividend income at current rates, compared to roughly $4,600 from a 10-year Treasury. The equity income carries more risk, including price volatility and the possibility of dividend cuts, but also offers the prospect of rising income as companies continue to raise payouts.
Risks income investors should watch
Consumer staples face persistent input cost pressures from commodities, labor, and transportation. Smucker and PepsiCo have offset these costs through pricing, but margin compression remains a risk if inflation reaccelerates. AbbVie faces patent-cliff dynamics as biosimilars erode Humira pricing power, though Skyrizi and Rinvoq growth is tracking ahead of expectations.
Interest rate risk also matters. If the Federal Reserve raises rates further, Treasury yields could climb above 5 percent, making dividend stocks less attractive on a relative basis. Conversely, if the economy slows and the Fed cuts rates, dividend growth stocks could outperform as investors rotate toward stable cash flows.
Stay ahead with our weekly newsletter
Get stock picks, market analysis, and strategy updates delivered to your inbox every week.
Subscribe to AlphaBetaStock’s free newsletter for daily market insights.
